Search for European Projects

4 European Projects Found

Searched on 125080 European Projects

 FINISHED 

DNA binding proteins for treatment of gain of function mutations (ALLELECHOKER)

Start date: Feb 1, 2013, End date: Jan 31, 2018,

Zinc finger (ZF) and transcription activator-like effector (TALE) based technologies are been allowing the tailored design of “artificial” DNA-binding proteins targeted to specific and unique DNA genomic sequences. Coupling DNA binding proteins to effectors domains enables the constitution of DNA binding factors for genomic directed transcriptional modulation or targeted genomic editing. We have d ...
Read Project

 1

 FINISHED 

DULBECCO TELETHON INSTITUTE-INTERNATIONAL MOBILITY FOR POSTDOCTORAL RESEARCH TRAINING (DTI-IMPORT)

Start date: Dec 1, 2012, End date: Nov 30, 2017,

With this proposal we are seeking an economical support from the European Union to implement an International Programme of Postdoctoral Research Training to enhance the international dimension of the fellows operating in the Dulbecco Telethon Institute (DTI) and to provide an excellent training to experienced researchers in the field of Research in the Biomedical Sciences that will likely contribu ...
Read Project

 1

 FINISHED 

Clinical trial of gene therapy for MPS VI - a severe lysosomal storage disorder (MEUSIX)

Start date: Dec 1, 2012, End date: Nov 30, 2017,

"Mucopolysaccharidosis VI (MPS VI, or Maroteaux-Lamy syndrome; OMIM #253200) is a rare lysosomal storage disease caused by deficient activity of arylsulfatase B (ARSB). MPS VI is characterized by growth retardation, corneal clouding, cardiac valve disease, organomegaly, skeletal dysplasia, without central nervous system involvement. Thus, systemic therapies targeting peripheral organs have the pot ...
Read Project

 9

 FINISHED 

Overcoming the challenge of large gene transfer for the therapy of inherited retinal diseases (RETGENTX)

Start date: Jan 1, 2012, End date: Dec 31, 2016,

Inherited retinal diseases (IRDs) cause blindness in over 200,000 individuals in Europe. The majority are due to mutations in genes expressed in photoreceptors (PR) in the retina. We have recently demonstrated the safety and efficacy of gene therapy for IRDs in patients with Leber congenital amaurosis (LCA). One of the major limitations to extend this clinical success to other blinding conditions ...
Read Project

 1